Neutrophil gelatinase-associated lipocalin (NGAL): A new marker of kidney disease

The incidence of both acute kidney injury (AKI, previously referred to as acute renal failure) and chronic kidney disease (CKD) is reaching epidemic proportions. In both situations, early intervention can significantly improve the prognosis. However, the paucity of early, predictive, non-invasive bi...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of clinical & laboratory investigation. Supplement Vol. 68; no. S241; pp. 89 - 94
Main Author: Devarajan, Peasad
Format: Journal Article
Language:English
Published: Norway Informa UK Ltd 01.01.2008
Taylor & Francis
Subjects:
Acute Disease
Acute kidney injury
acute renal failure
Acute-Phase Proteins - analysis
Acute-Phase Proteins - urine
biomarker
Biomarkers - analysis
Chronic Disease
chronic kidney disease
contrast nephropathy
Humans
Kidney Diseases - blood
Kidney Diseases - diagnosis
Kidney Diseases - urine
kidney transplantation
lipocalin, nephrotoxicity
Lipocalin-2
Lipocalins - analysis
Lipocalins - blood
Lipocalins - urine
Proto-Oncogene Proteins - analysis
Proto-Oncogene Proteins - blood
Proto-Oncogene Proteins - urine
ISSN:0036-5513, 0085-591X, 1502-7686
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of both acute kidney injury (AKI, previously referred to as acute renal failure) and chronic kidney disease (CKD) is reaching epidemic proportions. In both situations, early intervention can significantly improve the prognosis. However, the paucity of early, predictive, non-invasive biomarkers has impaired our ability to institute potentially effective therapies for these common clinical conditions in a timely manner. The current status of one of the most promising novel biomarkers, namely neutrophil gelatinase-associated lipocalin (NGAL), is presented in this review. The evidence for the role of NGAL measurements in a variety of clinical situations leading to AKI (cardiac surgery, kidney transplantation, contrast nephropathy, haemolytic uraemic syndrome and in the intensive care setting) or to CKD (lupus nephritis, glomerulonephritides, obstruction, dysplasia, polycystic kidney disease, IgA nephropathy) is explored. The emerging utility of standardized clinical platforms for reliable measurement of NGAL in plasma (Triage® NGAL Device; Biosite Incorporated) and urine (ARCHITECT® analyzer; Abbott Diagnostics) is also discussed. It will be important in future studies to validate the sensitivity and specificity of NGAL concentration measurements in clinical samples from large cohorts and from multiple clinical situations. Such studies will be facilitated by the anticipated widespread availability of standardized commercial tools in the near future.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
G. Jones, J. Coresh, R. Kettritz, E. Ritz.
Contributing to the discussion
Correspondence. Prasad Devarajan, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, MLC 7022, 3333 Burnet Avenue, Cincinnati, OH 45229-2029, USA. Tel: +1 513 636 4531. Fax: +1 513 636 7407. Email: prasad.devarajan@cchmc.org
ISSN:0036-5513
0085-591X
1502-7686
DOI:10.1080/00365510802150158